Sarepta Therapeutics

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, October 31, 2022
RNA, Duchenne muscular dystrophy, Sarepta, Financial compensation, Muscular dystrophy, GLOBE, Board, Investor, Employment, Degenerative disease, DMD, Sarepta Therapeutics, NASDAQ, Therapy, Gene editing, RSU, SRPT, Facebook

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 31,125 shares of Sarepta's common stock, and in the aggregate 16,075 restricted stock units (RSUs).
  • Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short.
  • We encourage investors and potential investors to consult our website regularly for important information about us.

Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, October 26, 2022
Company, LinkedIn, NASDAQ, Nasdaq, Sarepta Therapeutics, Interest, DMD, SRPT, RNA, Sarepta, GLOBE, Muscular dystrophy, Instagram, Gene editing, PIN, Twitter, Therapy, Duchenne muscular dystrophy, Degenerative disease, Investor application, Online shopping, Facebook

CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2022 financial results after the Nasdaq Global Market closes on Wednesday, November 2, 2022.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2022 financial results after the Nasdaq Global Market closes on Wednesday, November 2, 2022.
  • E.T., the Company will host a conference call to discuss its third quarter 2022 financial results.
  • Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short.
  • Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing.

Life sciences industry's highest achievers celebrated at prestigious Awards ceremony

Retrieved on: 
Thursday, October 27, 2022
Golodirsen, Johnson & Johnson, Growth, ANZ, Ecosystem, Murdoch University, Skin, Solution, Investment, Company, TGA, Radiopharmaceutical, Commer, Research, Achievement, USD, Food technology, Foundation, Neurology, Surgeon, FDA, PYC, Therapy, Patient, University, Multimedia, AUD, Health, Diagnosis, Biotechnology, Health Canada, Gynaecology, Map, Civil Rights Attorney's Fees Award Act of 1976, Innovation, Industry, COVID-19, Medical tourism, PSMA, Prostate cancer, Casimersen, Forrest, Molecular medicine, Biomedical Research, Ten Mile, Eteplirsen, Secondary research, University of Western Australia, Pathology, Otorhinolaryngology, Partnership, Sarepta Therapeutics, Leadership, Telescopic sight, Pharmaceutical industry, Medicine, Medical device, Renewable energy, Medical imaging, Telix

PERTH, Australia, Oct, 27, 2022 /PRNewswire/ -- Biotech's illustrious Industry Excellence Awards were announced today at the AusBiotech 2022 national conference in Perth – recognising outstanding contribution and achievement. The AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards recognise innovative companies and individuals in Australia's world-class biotechnology, medical technology and healthcare sectors.

Key Points: 
  • The AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards recognise innovative companies and individuals in Australia's world-class biotechnology, medical technology and healthcare sectors.
  • Dr Andrew Forrest AO and Nicola Forrest AO were also awarded the AusBiotech Life Sciences Legacy Award in recognition of their generous and active support of medical research and Australian life science innovation.
  • The discovery, development and commercialisation of biomedical research takes a global effort from diverse ecosystem including scientists, entrepreneurs, philanthropists and industry partners.
  • AusBiotech is a well-connected network of over 3,000 members in the life sciences, including therapeutics, medical technology (devices and diagnostics), food technology and agricultural sectors.

The Alliance for Regenerative Medicine Announces Election of 2023 Officers, Executive Committee, and Board of Directors

Retrieved on: 
Tuesday, October 11, 2022
CA, MBBS, Therapy, Hospital, Office of the Gene Technology Regulator, Pfizer, Organization, Cell, Patient, George Washington University, Mesa, MBA, MSF, Executive Committee, Entrepreneurship, Allergy, Asthma & Immunology Research, Novo Nordisk, Board, Treasurer, Intellia Therapeutics, GLOBE, Sarepta Therapeutics, Board of directors, ARM, Lonza, Center, Central Executive Committee of the Pakistan Peoples Party, Regenerative medicine, Leadership, Pharmaceutical industry, Management, Cabinetry, Director

Carlsbad, CA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announced the election of its 2023 Officers, Executive Committee, and Board of Directors.

Key Points: 
  • Carlsbad, CA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announced the election of its 2023 Officers, Executive Committee, and Board of Directors.
  • The Executive Committee and Board of Directors oversee the formation and execution of ARMs strategic priorities and focus areas.
  • We are delighted to welcome our 2023 Officers, Executive Committee members and Board of Directors, said ARMs Chief Executive Officer Timothy D. Hunt.
  • Chair of the Board, Homology Medicines
    * Faraz Ali, MBA Chief Executive Officer, Tenaya Therapeutics
    Robert Ang, MBBS, MBA Chief Executive Officer, Vor Biopharma
    * Catherine Bollard, M.B.Ch.B., M.D.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, September 30, 2022
SRPT, Employment, Twitter, Gene editing, Financial compensation, Muscular dystrophy, LinkedIn, Degenerative disease, Therapy, Instagram, Sarepta Therapeutics, Investor, NASDAQ, Board, RNA, GLOBE, DMD, Sarepta, RSU, Duchenne muscular dystrophy, Pharmaceutical industry, Facebook

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 53,575 shares of Sarepta's common stock, and in the aggregate 27,525 restricted stock units (RSUs).
  • Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short.
  • We encourage investors and potential investors to consult our website regularly for important information about us.

Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy

Retrieved on: 
Thursday, September 29, 2022
SRPT, Dystrophin, Safety, COVID-19, Roche, RPD, Twitter, FDA, Food, Disease, Gene editing, Biologics license application, Muscular dystrophy, Muscle weakness, LinkedIn, Company, Sarepta Therapeutics, Four Year Plan, Degenerative disease, Review, Partnership, Heart failure, Therapy, NSAA, U.S. Securities and Exchange Commission, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Risk, Walking, Instagram, United States Patent and Trademark Office, Investor Protection and Securities Reform Act of 2010, Goal, Annual report, Patent, Orphan drug, Fast Track, EC, NASDAQ, Heart, RNA, Security (finance), GLOBE, BLA, DMD, SEC, Union, Mutation, Sarepta, Duchenne muscular dystrophy, Pharmaceutical industry, Medical device, Duchenne, Facebook

Sarepta has proposed its fully-enrolled study EMBARK (Study SRP-9001-301) as the post-marketing confirmatory study to support the accelerated approval.

Key Points: 
  • Sarepta has proposed its fully-enrolled study EMBARK (Study SRP-9001-301) as the post-marketing confirmatory study to support the accelerated approval.
  • Duchenne muscular dystrophy (DMD) is a rare, fatal neuromuscular genetic disease that occurs in approximately one in every 3,500-5,000 newborn males worldwide.
  • We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development.
  • For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta.

Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027

Retrieved on: 
Wednesday, September 14, 2022
Observation, SRPT, Time, Gene editing, Risk, Sale, Securities Act of 1933, Muscular dystrophy, Debt-to-GDP ratio, Degenerative disease, News, Therapy, Person, Exercise, Rule, Boston bid for the 2024 Summer Olympics, Note, NASDAQ, SEC Rule 144A, RNA, GLOBE, DMD, SEC, Sarepta Therapeutics, The Act, Duchenne muscular dystrophy, Security (finance), Cryptocurrency

Sarepta has also granted the initial purchasers of the notes an option to purchase up to an additional $150 million aggregate principal amount of notes.

Key Points: 
  • Sarepta has also granted the initial purchasers of the notes an option to purchase up to an additional $150 million aggregate principal amount of notes.
  • The sale of the notes to the initial purchasers is expected to settle on September 16, 2022, subject to customary closing conditions.
  • Sarepta anticipates that, along with current cash and projected revenue, this offering is sufficient to fund operations to profitability.
  • If the initial purchasers of the notes exercise their option to purchase additional notes, Sarepta expects to enter into additional capped call transactions with the option counterparties.

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic Year

Retrieved on: 
Wednesday, September 7, 2022
RNA, Muscular dystrophy, Program, Degenerative disease, Therapy, NASDAQ, Gene editing, Investors United (School of Real Estate Investing), Letter, List of highways numbered 79, Sibling, Â, LinkedIn, Diagnosis, Duchenne muscular dystrophy, SRPT, Government, Student, DMD, GLOBE, Instagram, Twitter, Exon, Growth, Family, Sarepta Therapeutics, Duchenne, Facebook

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced twenty recipients of Route 79, The Duchenne Scholarship Program for the 2022-2023 academic year. The Program was created in 2018 to recognize exceptional individuals living with Duchenne muscular dystrophy as they pursue their post-secondary education. Now in its fifth year, the Program was expanded to include siblings of individuals with Duchenne in recognition of the impact that a diagnosis of Duchenne may have on the entire family. Recipients of the scholarship are chosen by an independent selection committee composed of Duchenne community members, who consider each applicant’s community involvement and personal essay. Each student will receive a scholarship of up to $5,000.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.(NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced twenty recipients of Route 79, The Duchenne Scholarship Program for the 2022-2023 academic year.
  • Recipients of the scholarship are chosen by an independent selection committee composed of Duchenne community members, who consider each applicants community involvement and personal essay.
  • On behalf of Sarepta and the selection committee, we are thrilled to announce the recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 academic year.
  • Route 79, TheDuchenne Scholarship Program is designed to help students with Duchenne and siblings of individuals living with Duchenne pursue their post-secondary educational goals.

Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy

Retrieved on: 
Tuesday, September 6, 2022
Security (finance), COVID-19, Dystrophin, RNA, Safety, Muscular dystrophy, United States Patent and Trademark Office, Degenerative disease, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, Patent, NASDAQ, Gene editing, Investor Network on Climate Risk, Risk, Food, LinkedIn, Union, SEC, SRPT, Sarepta, Duchenne muscular dystrophy, PMO, Magnesium, Goal, Review, U.S. Securities and Exchange Commission, DMD, GLOBE, Instagram, Company, FDA, Twitter, Biomarker, Sarepta Therapeutics, RNA transfection, Annual report, Urine, Patient, Pharmaceutical industry, Vaccine, Part, Facebook

After discussions with FDA and as part of the lift, Sarepta will adjust the global trial protocol to include expandedmonitoringof urine biomarkers.

Key Points: 
  • After discussions with FDA and as part of the lift, Sarepta will adjust the global trial protocol to include expandedmonitoringof urine biomarkers.
  • We would like to thank FDA for working closely with us to expeditiously resolve this clinical hold.
  • Sarepta is committed to the SRP-5051 program and excited about the PPMO platform as a next-generation exon-skipping approach for the treatment of Duchenne.
  • For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta.

Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, September 6, 2022
Software, RNA, Muscular dystrophy, Degenerative disease, Therapy, NASDAQ, Gene editing, Morgan, Investor application, LinkedIn, Sheraton New York Times Square Hotel, Duchenne muscular dystrophy, SRPT, Sarepta, DMD, GLOBE, Instagram, Conference, Twitter, Sarepta Therapeutics, Event, Facebook

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 12:30 p.m. E.T.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 12:30 p.m. E.T.
  • Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short.
  • Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing.
  • We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com .